Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.

被引：0

作者：

Strati, Paolo

Leslie, Lori Ann

Shiraz, Parveen

Budde, L. Elizabeth

Oluwole, Olalekan O.

Ulrickson, Matthew

Ramakrishnan, Aravind

Sun, Jennifer

Shen, Rhine

Kanska, Justyna

McCroskery, Peter

Dong, Jinghui

Schupp, Marco Andreas

Xu, Hairong

Patel, Krish

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[2] John Theurer Canc Ctr, Hackensack, NJ USA

[3] Stanford Univ, Stanford, CA USA

[4] City Hope Natl Med Ctr, Duarte, CA USA

[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[7] Texas Transplant Physician Grp, Austin, TX USA

[8] Gilead Co, Kite, Santa Monica, CA USA

[9] Swedish Canc Inst, Seattle, WA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7567

引用

页数：1

共 50 条

[41] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[42] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[43] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Maloney, David G.
Kuruvilla, John
Fox, Christopher P.
Cartron, Guillaume
Li, Daniel
Hasskarl, Jens
Bonner, Ashley
Zhang, Yixie
Liu, Fei Fei
BLOOD, 2020, 136
[44] Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Cook, Michael Roderick
Shouval, Roni
Perales, Miguel-Angel
Bezerra, Evandro
Niu, Alex
Dahiya, Saurabh
Nastoupil, Loretta J.
Jacobson, Caron A.
Budde, L. Elizabeth
Olson, Amanda L.
Logan, Brent R.
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Kim, Jenny J.
Smith, Harry W.
Lee, Andrew
Sun, Fang
Pasquini, Marcelo
Locke, Frederick L.
BLOOD, 2023, 142
[45] Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL)
Miles, Brodie
Mao, Daqin
Vardhanabhuti, Saran
To, Christina Ann
Schupp, Marco Andreas
Shahani, Shilpa
Xu, Hairong
Munoz, Javier
Westin, Jason
Shen, Rhine
Filosto, Simone
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Chaganti, Sridhar
Cwynarski, Kate
Cunningham, David
Locke, Frederick L.
Miklos, David B.
Jacobson, Caron A.
Perales, Miguel-Angel
Kersten, Marie Jose
Oluwole, Olalekan O.
Ghobadi, Armin
Rapoport, Aaron P.
McGuirk, Joseph P.
Pagel, John M.
Munoz, Javier
Farooq, Umar
van Meerten, Tom
Reagan, Patrick M.
Sureda, Anna
Flinn, Ian W.
Vandenberghe, Peter
Song, Kevin W.
Dickinson, Michael
Minnema, Monique C.
Riedell, Peter A.
Leslie, Lori A.
Yang, Yin
Filosto, Simone
Schupp, Marco
To, Christina
Cheng, Paul
Gordon, Leo I.
Radford, John
Westin, Jason R.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
[47] 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)
Chavez, Julio C.
Dickinson, Michael
Munoz, Javier L.
Ulrickson, Matthew L.
Thieblemont, Catherine
Oluwole, Olalekan O.
Herrera, Alex F.
Ujjani, Chaitra S.
Lin, Yi
Riedell, Peter A.
Kekre, Natasha K.
de Vos, Sven
Lui, Christine
Wulff, Jacob
Williams, Chad M.
Peng, Weixin
Kloos, Ioana
Xu, Hairong
Neelapu, Sattva S.
BLOOD, 2023, 142
[48] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Bharadwaj, Sushma
Lau, Eric
Goyal, Anmol
Hamilton, Mark P.
Srinagesh, Hrishikesh
Jensen, Alexandria
Syal, Shriya
Mallampet, Jayasindhu
Latchford, Theresa
Sahaf, Bita
Weng, Wen-Kai
Smith, Melody
Maecker, Holden T.
Frank, Matthew J.
Miklos, David B.
Dahiya, Saurabh
BLOOD, 2023, 142
[49] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Jacobson, C. A.
Jacobsen, E.
Miklos, D. B.
Lekakis, L. J.
Braunschweig, I
Oluwole, O. O.
Lin, Y.
Siddiqi, T.
Deol, A.
Reagan, P. M.
Farooq, U.
Bot, A.
Jiang, Y.
Rossi, J. M.
Xue, A.
Go, W. Y.
Neelapu, Sattva S.
HAEMATOLOGICA, 2018, 103 : 95 - 96
[50] Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Dickinson, Michael
Ulrickson, Matthew L.
Oluwole, Olalekan O.
Herrera, Alex F.
Thieblemont, Catherine
Ujjani, Chaitra S.
Lin, Yi
Riedell, Peter A.
Kekre, Natasha
de Vos, Sven
Yang, Yin
Milletti, Francesca
Goyal, Lovely
Kawashima, Jun
Chavez, Julio C.
BLOOD, 2020, 136

← 1 2 3 4 5 →